Incredible progress is being made in kidney cancer treatment.
ESCOs are accountable for clinical quality outcomes and financial outcomes.
With an ever-expanding array of options for treating advanced prostate cancer, it is important to remain focused on the best treatment path for each patient.
CMS also has upcoming plans to impose fiscal penalties related to dialysis treatment.
Effective clinical trial design and ultimately drug approval require careful consideration of the endpoints selected.
Patient-centeredness should become a core component of clinical practice guidelines, according to Dr Kalantar-Zadeh.
The guidelines state that clinicians should offer blue light cystoscopy, if available, as an adjunct to traditional white light cystoscopy (WLC) to increase tumor detection and decrease recurrence.
To avoid CKD, the guidelines now provide detailed review of the risk/benefit profile comparing partial to radical nephrectomy.
Both urologists and nephrologists provide follow-up and continuity of care to patients after cancer nephrectomy.
Data from MagnaSafe suggest that MRIs for patients with pacemakers/ICDs can be performed safely.
Efforts should be directed at making nephrology more appealing to recruit more trainees.
Adjuvant treatments for RCC must be prioritized by physicians because ultimately value is determined by how medicine is practiced.
Renal and Urology News Articles
- Novel Albuminuria Endpoints May Improve CKD Progression Trials
- Comorbidities Adversely Linked to Cancer Trial Participation
- Global Demand for Bladder Cancer Treatment Threatens Supply in 2019
- Opioids Now More Deadly for Americans Than Traffic Accidents
- New Predictor of In-Hospital Acute Kidney Injury Identified
Sign Up for Free e-newsletters
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)